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Abstract 
Objective: To describe the association of bone marrow lesions (BMLs) present on two 
different MRI sequences with clinical outcomes, cartilage defect progression, cartilage 
volume loss over 2.7 years, and total knee replacement (TKR) over 13.3 years. 
Methods: 394 participants (50-80 years) were assessed at baseline and 2.7 years. BML 
presence at baseline was scored on T1-weighted fat-suppressed 3D gradient-recalled 
acquisition (T1) and T2-weighted fat-suppressed 2D fast spin-echo (T2) sequences. Knee 
pain, function, and stiffness were assessed using WOMAC. Cartilage volume and defects 
were assessed using validated methods. Incident TKR was determined by data linkage.  
Results: BMLs were mostly present on both MRI sequences (86%). BMLs present on T2, 
T1, and both sequences were associated with greater knee pain and functional limitation 
(odds ratio=1.49 to 1.70; all P<0.05). Longitudinally, BMLs present on T2, T1, and both 
sequences were associated with worsening knee pain (β=1.12 to 1.37, respectively; P<0.05) 
and worsening stiffness (β=0.45 to 0.52, respectively; all P<0.05) but not worsening 
functional limitation or total WOMAC. BMLs present on T2, T1, and both sequences 
predicted site-specific cartilage defect progression (relative risk=1.22 to 4.63; all P<0.05) 
except at the medial tibial and inferior patellar sites. Lateral tibial and superior patellar BMLs 
present on T2, T1, and both sequences predicted site-specific cartilage volume loss (β= -
174.77 to -140.67; P<0.05). BMLs present on T2, T1, and both sequences were strongly 
associated with incident TKR.  
Conclusions: BMLs can be assessed on either T2 or T1-weighted sequences with no clinical 
predictive advantage of either sequence. 
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INTRODUCTION 1 
Subchondral bone marrow lesions (BMLs), visible on magnetic resonance imaging (MRI) 2 
have been shown to be an important feature in osteoarthritis (OA). BMLs are associated with 3 
pain (1-4), predict cartilage defect progression and cartilage volume loss (5-7), and total joint 4 
replacement (TKR) surgery (4, 8-10). 5 
 Conventionally, BMLs are assessed on fluid-sensitive MRI sequences such as T2-6 
weighted fat saturation, short tau inversion recovery (STIR), intermediate weighted fat 7 
saturation (IW-FS), and proton density fat saturation (PD-FS) , although they can be detected 8 
using other MRI sequences (8, 11, 12). Previous reports indicate that gradient recalled echo 9 
(GRE)-type MRI sequences such as T1-weighted  gradient echo and spoiled gradient recalled 10 
acquisition in steady state (SPGR) are insensitive to marrow abnormalities and may 11 
underestimate the lesion size, compared to fluid sensitive sequences (13-15). Although many 12 
studies have compared the performance of different MRI sequences in regard to their ability 13 
to detect BMLs (prevalence), reliability, and sensitivity to change (15-20), there are limited 14 
studies on how BMLs on different MRI sequences correlate with clinical outcomes.  15 
 In a recent study in a pain-free knee cohort, BMLs present on both T2- and T1-16 
weighted fat saturation MRI sequences were associated with medial tibial cartilage volume 17 
loss and incident knee pain over 2 years (21). Furthermore, in separate studies, its been 18 
shown that BMLs identified on T2- and T1-weighted images predict joint replacement 19 
surgery among people with OA (8, 10). This study aimed to determine the association of 20 
BMLs detected on two different MRI sequences with pain, physical function limitation, 21 
stiffness, cartilage defect progression, and cartilage volume loss in older adults over 2.7 22 
years, as well as knee joint replacement surgery over 13.3 years. Given that BMLs generally 23 
appear larger on T2-weighted MRI compared to T1-weighted MRI (14, 15), we hypothesised 24 
that BMLs would be easier to detect on T2-weighted MRI sequences and would be more 25 
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strongly associated  with  clinical outcomes compared to BMLs present on T1-weighted MRI 26 
sequences.   27 
METHODS 28 
Participants  29 
This study was a part of the Tasmanian Older Adult Cohort (TASOAC) study, an ongoing 30 
prospective, population-based study aimed at identifying the environmental, genetic, and 31 
biochemical factors associated with the development and progression of OA at multiple sites 32 
(hand, knee, hip, and spine). Participants between the ages of 50 and 80 years were randomly 33 
selected from the electoral roll in Southern Tasmania (population, 229,000), with an equal 34 
number of men and women. The overall response rate was 57%. Participants were excluded 35 
if they were institutionalised or reported a contraindication to having a right knee MRI scan 36 
(e.g. implanted pacemaker, metal sutures, presence of shrapnel or iron filings in the eye, 37 
claustrophobia, right knee replacement, knee too large for scanner). Figure 1 shows the study 38 
flowchart. Of all initially eligible participants, 1,100 enrolled in the study, and 1,099 attended 39 
a baseline clinic between March 2002 and September 2004. Follow-up data were collected 40 
for 875 eligible participants at a subsequent clinic approximately 2 to 3 years later. The MRI 41 
machine was decommissioned halfway through the follow-up period; therefore, MRI scans 42 
were available for approximately half of the follow-up participants.  43 
All research conducted was in compliance with the Declaration of Helsinki and was approved 44 
by the Southern Tasmanian Health and Medical Human Research Ethics Committee. All 45 
subjects gave informed written consent. 46 
Anthropometrics 47 
Weight was measured to the nearest 0.1 kg (with shoes, socks, and bulky clothing removed) 48 
using a single pair of electronic scales (Seca Delta Model 707). Height was measured to the 49 
nearest 0.1 cm (with shoes and socks removed) using a stadiometer. Body mass index (BMI) 50 
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was calculated as kilograms per square meter.  51 
Radiographic knee OA  52 
A standing anteroposterior semi-flexed view of the right knee with 15° of fixed knee flexion 53 
was performed at baseline and scored individually for osteophytes and joint space narrowing 54 
on a scale of 0 to 3 (0=normal and 3=severe) according to the Altman atlas (22) as previously 55 
described (23). The presence of radiographic OA was defined as any score ≥1 for joint space 56 
narrowing or osteophytes.  57 
Magnetic resonance imaging 58 
MRI of the right knee was acquired at baseline and follow-up with a 1.5-T whole-body 59 
magnetic resonance unit (Picker, Cleveland, OH, USA) by using a commercial 60 
transmit/receive extremity coil. Image sequences included the following: (a) a T1-weighted 61 
fat saturation three-dimensional (3D) gradient-recalled acquisition (T1-w GRE MRI) in the 62 
steady state; flip angle, 30 degrees; repetition time, 31 milliseconds; echo time, 6.71 ms; field 63 
of view, 16 cm; 60 partitions, 512 × 512-pixel matrix; acquisition time, 5 minutes 58 64 
seconds; one acquisition; sagittal images were obtained at a slice thickness of 1.5 mm without 65 
a interslice gap; and (b) a T2-weighted fat saturation two-dimensional (2D) fast spin echo 66 
(T2-w FSE MRI), flip angle, 90 degrees; repetition time, 3,067 milliseconds; echo time, 112 67 
milliseconds; field of view, 16 cm, 15 partitions, 228 × 256-pixel matrix; sagittal images 68 
were obtained at a slice thickness of 4 mm with an interslice gap of 0.5 to 1.0 mm. 69 
Bone marrow lesions  70 
Subchondral BMLs were assessed on T2-w FSE and T1-w GRE fat saturation MR images by 71 
using OsiriX software at the medial and lateral sites of the femur and tibia, and the superior 72 
and inferior sites of the patella at baseline. BMLs were defined as areas of increased signal 73 
intensity on T2-w FSE and T1-w GRE, located immediately under the articular cartilage. One 74 
trained observer measured the BMLs on each sequence by measuring the maximum area of 75 
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the lesion on a single slice where the area appeared the largest in mm2 using software cursors. 76 
If more than one lesion was present at the same site, the BML with the largest size was used. 77 
Baseline and follow-up MRI images were read paired with the chronological order known to 78 
the observer. Intra-observer reliability was assessed in 40 randomly selected subjects after a 79 
2-week interval between the readings. The intra-class correlation coefficient (ICC) using two-80 
way mixed-effects model (24) was 0.98 (95% CI; 0.96, 0.99) for T2 and 0.94 (95% CI; 0.90, 81 
0.96) for T1-weighted sequences. For analysis, BMLs were categorised into three groups: 1) 82 
BMLs present on T2-weighted MRI (T2-w FSE), 2) BMLs present on T1-weighted MRI (T1-83 
w GRE), and 3) BMLs present on both T2-weighted and T1-weighted MRI (T1 and T2).  84 
Cartilage morphology evaluation  85 
Cartilage defects were assessed by a trained observer at baseline and follow-up on T1-86 
weighted MR images (score range, 0 – 4), as previously described : grade 0 = normal 87 
cartilage; grade 1 = focal blistering and intra-cartilaginous low-signal intensity area with an 88 
intact surface and base; grade 2 = irregularities on the surface or base and loss of thickness < 89 
50%; grade 3 = deep ulceration with loss of thickness > 50%; and grade 4 = full-thickness 90 
chondral wear with exposure of subchondral bone. A cartilage defect also had to be present 91 
on at least 2 consecutive slices. The cartilage was considered to be normal if the band of 92 
intermediate signal intensity had a uniform thickness. If more than one defect was present on 93 
the same site, the highest score was used. Medial tibial, lateral tibial, medial femoral, lateral 94 
femoral, and patellar compartments were measured. Baseline and follow-up images were read 95 
at different time points. The baseline scores were available to the reader when assessing the 96 
follow-up scores. Intraobserver repeatability was assessed in 50 subjects with at least 1-week 97 
between the 2 measurements with ICC of 0.93, 0.92, 0.95, 0.80, and 0.94 at the medial tibia, 98 
medial femur, lateral tibia, lateral femur, and patellar respectively (25). Change in cartilage 99 
defect score from baseline to follow-up was dichotomised to 0 and 1: 0 representing no 100 
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change or a decrease in cartilage defects and 1 representing an increase of 1 or more on the 0 101 
– 4 scale.  102 
Knee tibial and patellar cartilage volume was measured by a trained observer on T1-weighted 103 
MR images at baseline and follow-up by means of image processing on an independent 104 
workstation using Osiris software as previously described (25, 26). The volumes of 105 
individual cartilage plates (medial tibia and lateral tibia) were isolated from the total volume 106 
by manually drawing disarticulation contours around the cartilage boundaries on a section by 107 
section basis. These data were then re-sampled by means of bilinear and cubic interpolation 108 
(area of 312 × 312 mm and 1.5 mm thickness, continuous sections) for the final 3D 109 
rendering. The baseline and follow-up images were read at different time points. The baseline 110 
cartilage volume value was available to the reader when assessing the follow-up scans. The 111 
coefficient of variation (CV) was 2.1% for the medial tibia, 2.2% for the lateral tibia, and 112 
2.6% for patella. 113 
Knee femoral cartilage volume was determined at baseline and follow-up by means of image 114 
processing on an independent workstation using CartiscopeTM (ArthroLab Inc., Montreal, 115 
Quebec, Canada), as previously described (27-29). The quantitative segmentation of the 116 
cartilage- synovial interfaces was carried out with the semi-automatic method under reader 117 
supervision and with corrections when needed. Cartilage volume was evaluated directly from 118 
a standardized view of 3D cartilage geometry as the sum of elementary volumes. Baseline 119 
and follow-up images were read paired with chronological order known to the reader. The 120 
coefficient of variation percentage (CV) was approximately 2% (27). The cartilage volume 121 
assessment was done for the medial and lateral condyles delineated by the Blumensaat’s line .  122 
WOMAC scores 123 
Knee pain, physical function limitation, and stiffness were assessed using the self-124 
administered Western Ontario and McMaster Universities OA Index (WOMAC) (30) scale, 125 
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which was scored using a 10-point numeric rating scale from 0 (no pain, no function 126 
limitation, and no stiffness) to 9 (most severe pain, most severe physical function limitation, 127 
and most severe stiffness) (30) at baseline and follow-up. There are 5 components of pain, 17 128 
of function limitation and two of stiffness included.  Each of the subscales are summed to 129 
form a total score for pain (range 0-45), function limitation (range 0-153) and stiffness (range 130 
0-18). The total WOMAC score was calculated by summing pain, function limitation and 131 
stiffness total scores (range 0- 216) (30). For cross-sectional analysis, we categorised the 132 
subcales into three levels (none, mild, moderate to severe). This categorisation was done due 133 
to non-normally distributed WOMAC data. These levels were based on pain cut-offs used by 134 
an OA Expert Group in the Global Burden of Disease (GBD) 2010 study (31). Total pain 135 
score was categorised as 0 (none), 1-13 (mild), and 14-45 (moderate to severe). Total 136 
function limitation score was categorised as 0 (none), 1-45 (mild), and 46-153 (moderate to 137 
severe). Total stiffness score was categorised as 0 (none), 1-4 (mild), 5-18 (moderate to 138 
severe). Total WOMAC score was categorised as 0 (none), 1-64 (mild), 65-216 (moderate to 139 
severe). For longitudinal analysis, change in WOMAC scales was calculated as follow-up 140 
minus baseline.  141 
Total knee replacement (TKR) surgery 142 
The incidence of TKR surgery was determined by data linkage to the Australian Orthopaedic 143 
Association National Joint Replacement Registry (AOANJRR) between 1 March 2002 and 144 
21 September 2016. AOANJRR started data collection in Tasmania in September 2000 and 145 
collects data from both public and private hospitals. Data validation against State and 146 
Territory Health Department data is done using a sequential multi-level matching process 147 
(32). Identifying information such as first name, last name, sex, date of birth, current and 148 
historical addresses were provided to AOANJRR, which were used to identify participants 149 
who had a TKR. Ethical approval for data linkage was obtained from the Tasmanian Health 150 
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and Medical Human Research Ethics Committee. 151 
Comorbidities and Pain Medication Use 152 
Participants used a self-reported questionnaire to report whether or not they had any of the 153 
following comorbidities (yes/no); diabetes, heart attack, hypertension, thrombosis, asthma, 154 
bronchitis/emphysema, osteoporosis, hyperthrodism, hypothyroidism, rheumatoid arthritis, 155 
and other major illness. They also used a self-reported questionnaire to list the pain 156 
medications they were taking (medication name, dose and frequency).  157 
Statistical Analysis  158 
The exposure for all analyses were BMLs present on T2-w FSE; BMLs present on T1-w 159 
GRE; and BMLs present on both MRIs. Five outcomes were analysed and fitted into a 160 
separate model for the three exposures; baseline WOMAC scales, change in WOMAC scales, 161 
worsening or stabilising of site-specific cartilage defects, change in cartilage volume, and 162 
incident of TKR.  163 
Adjacent category ordinal logistic regression was used to estimate the association of BMLs 164 
on T1, T2, and both MRI sequences with baseline categories of knee pain, physical function 165 
limitation, stiffness and total WOMAC. Multivariable models were adjusted for age, sex, 166 
BMI, and radiographic OA. Standard errors were adjusted to account for any correlation of 167 
observations for the same individual (i.e. BMLs present on both MRI sequences). 168 
Linear regression was used to estimate the association of BMLs present on T1-w GRE, T2-w 169 
FSE, and both MRI sequences with change in WOMAC scales in separate models. Standard 170 
errors were adjusted to account for any correlation of observations for the same individual. 171 
Multivariable models were adjusted for age, sex, BMI in the first instance, then additionally 172 
for radiographic OA and baseline WOMAC score. The outcome variable was transformed 173 
using Box-Cox transformation to satisfy model assumptions.   174 
Site-specific associations between BMLs and cartilage defects were defined as the 175 
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association within the same site (e.g. medial tibial BMLs predicting medial tibial cartilage 176 
defect worsening). Log binomial regression was used to estimate the risk of worsening site-177 
specific cartilage defects over 2.7 years for baseline BMLs, adjusted for age, sex, and BMI 178 
and baseline cartilage defect score.  179 
Multilevel mixed-effects linear regression was used to estimate the longitudinal association 180 
of baseline BMLs with cartilage volume loss over 2.7 years. Point estimates of change in 181 
cartilage volume over 2.7 years for those with BMLs at baseline compared to those without 182 
BMLs at baseline were reported. Multivariable models were adjusted for age, sex, and BMI.  183 
Due to perfect prediction of BMLs with TKR (i.e. all those participants who underwent TKR 184 
surgery had a BML at baseline) we were unable to model this data and present it 185 
descriptively.   186 
We conducted a sensitivity analysis to examine whether number of comorbidities and pain 187 
medication use to examine whether these factors were confounders.  188 
All statistical analyses were performed using Stata 14 (Stata-Corp, College Station, Texas, 189 
USA). The significant p-value was set at the value of less than 0.05 (two-tailed).  190 
RESULTS 191 
Characteristic of participants  192 
The study sample contained 394 participants who had MRI measures at baseline and the 2-193 
year follow-up. There were no significant differences  in participant characteristics, including 194 
age, sex, BMI, baseline cartilage defects, and cartilage volume, between the study sample 195 
(n=394) and the remainder of the cohort (n=705) who did not have MRI scans at follow-up. 196 
The characteristics of the participants stratified by BMLs on any of the MRI sequences at 197 
baseline, are shown in Table 1. There were no significant differences in terms of age, sex, 198 
BMI, radiographic OA, WOMAC scales, total cartilage volume at baseline, and absolute 199 
change in total cartilage volume between those with and without baseline BMLs. Prevalence 200 
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of any cartilage defects at baseline, an increase in cartilage defect score and incident TKR 201 
was higher in those with baseline BMLs.   202 
BML prevalence and size 203 
231 (59%) participants had BMLs on at least one sequence. There were 388 BMLs detected 204 
on T2-w FSE and 378 BMLs detected on T1-w GRE. 354 (86%) of BMLs were detected on 205 
both MRI sequences and very few BMLs were detected on only one of the sequence types 206 
(i.e. 34 (8%) BMLs only on T2-w FSE and 24 (6%) only on T1-w GRE) as shown in Figure 207 
2. An example of this is presented in Figure 3. For those BMLs present on both sequences, 208 
while the size differences were not statistically significant, overall, mean area for total BMLs 209 
on T2-w FSE were slightly larger (Figure 4).  210 
Knee pain, functional limitation, stiffness and overall disability (total WOMAC score) 211 
Table 2 shows cross-sectional associations between BMLs present on T2-w FSE, T1-w GRE, 212 
and both MRI sequences and baseline category of knee pain, physical function limitation, 213 
stiffness, and total WOMAC score. Presence of BMLs on T2-w FSE, T1, and both MRI 214 
sequences at baseline were associated with increased odds of moving to a higher category of 215 
knee pain, physical function limitation, and total WOMAC score compared to the reference 216 
group with no BMLs. The effect sizes were similar for each sequence and remained 217 
unchanged and significant after adjustment for age, sex, BMI, and further adjustment for 218 
radiographic OA. Participants with a BML present on T2-w FSE, T1 and both MRI 219 
sequences were consistently estimated to have increased odds of moving to a higher category 220 
of stiffness but evidence for the association was weaker. 221 
We next examined whether the presence of BMLs T2-w FSE, T1, and both MRI sequences 222 
compared to the reference group with no BMLs was associated with changes in knee pain, 223 
physical function limitation, stiffness, and total WOMAC score over 2.7 years (Table 3). 224 
BMLs present on T2-w FSE, T1, and both MRI sequences were associated with the 225 
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worsening of pain and stiffness over 2.7 years, with similar effect sizes, after adjustment for 226 
age, sex, BMI, radiographic OA, and baseline WOMAC score. There was no evidence for an 227 
association between BMLs present on T2-w FSE, T1, or both MRI sequences with changes in 228 
physical function limitation and total WOMAC score in unadjusted or adjusted analyses.   229 
Cartilage defects 230 
Table 4 shows the relative risks of worsening site-specific cartilage defects over 2.7 years for 231 
BMLs present on T2-w FSE, T1, and both MRI sequences. Presence of BMLs on T2 T2-w 232 
FSE T1, and both MRI sequences were associated with a higher risk of site-specific cartilage 233 
defect worsening over 2.7 years in adjusted analysis at all sites, except medial tibial and 234 
inferior patellar. The relative risk estimates for each site were of a similar magnitude for the 235 
three sequence types, with the largest effect observed for the lateral femoral site.  236 
Cartilage volume loss  237 
Table 5 shows estimated changes in site-specific cartilage volume over 2.7 years for site-238 
specific BMLs present on T2-w FSE, T1, and both MRIs, compared to the reference group 239 
with no BMLs.  The presence of BMLs was associated with significantly greater cartilage 240 
volume loss at the lateral tibial and superior patellar for all MRI sequences. Increased 241 
cartilage volume loss was also associated with the presence of medial femoral BMLs 242 
identified on T2-w FSE, and with  lateral tibiofemoral BMLs identified on both MRI 243 
sequences and on T2-w FSE, but not for BMLs on T1-w GRE. While there was no evidence 244 
for an association between BMLs and site-specific cartilage volume loss at the medial tibial, 245 
lateral femoral, inferior patellar, medial tibiofemoral, total tibiofemoral and overall sites, the 246 
effect size estimates were consistently negative.  247 
Total knee replacement (TKR) 248 
6% of our study population had TKR (19 cases). 100% of TKR participants had a BML on 249 
both MRI sequences and on T1-w GRE. 95% of TKR participants had a BML on T2-w FSE. 250 
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This indicates BMLs were a very strong predictor of TKR on each sequence type. We were 251 
not able to model this data due to the perfect prediction  252 
Further adjustment of all our presented models for number of comorbidities and use of pain 253 
medication did not change effect sizes by more than 10%, data not shown.    254 
 255 
DISCUSSION 256 
This study describes associations between BMLs detected on two different MRI sequences 257 
with clinical outcomes in OA including pain, function, stiffness, cartilage damage and loss, 258 
and TKR surgery. We found that subchondral BMLs were commonly seen on both T2-w FSE 259 
and T1-w GRE sequences in an older adult population. While the difference in BML size on 260 
each sequence was not statistically significant, BML area was slightly larger on the T2-w 261 
FSE sequences compared to T1-w GRE sequences. Despite this, contrary to our hypothesis, 262 
associations with clinical outcomes including symptoms, cartilage damage and loss, and TKR 263 
were similar. This suggests that either T2-w FSE or T1-w GRE MRI sequences could be used 264 
separately to assess BMLs.  265 
Our study found that 86% of BMLs were seen on both MRI sequences in our sample 266 
of community-dwelling older adults.  Prevalence assessments for BMLs in previous studies 267 
vary widely. One study reported 74% in community-dwelling adults without knee pain (21); 268 
whereas, another study reported 75% in knees with and without medial joint space narrowing 269 
(33). Our rate of BMLs detected on both MRI sequences is higher than the previous studies. 270 
A number of factors may contribute to this inconsistency including the use of different 271 
sequence types, study populations, study sizes, and different BML scoring systems and 272 
readers. 273 
 There have been limited studies evaluating how BMLs on different MRI sequences 274 
correlate with clinically important outcomes. Recently Wluka et al. (21) reported that BMLs 275 
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present on both T1- and T2-weighted MRI sequences were associated with increased 276 
cartilage loss and incident knee pain compared to BMLs seen only on T2-weighted 277 
sequences. These findings support recommendations suggesting a combination of both fluid-278 
sensitive and GRE-type MRI sequences should be used. However, our study did not find this.  279 
We found that BMLs were typically seen on both MRI sequences, and were equivalently 280 
associated with symptoms, cartilage damage and loss, and TKR surgery. This suggests that 281 
there is no meaningful difference in prediction of clinically important outcomes using either 282 
sequence. Furthermore, in studies where both fluid-sensitive and GRE-type MRI sequences 283 
are not available, either sequence could be used for clinical research. 284 
 There is great debate about the ideal sequence to assess BMLs. Several previous studies 285 
have been conducted comparing the performance of different MRI sequences in regard to 286 
BML detection, reliability and sensitivity to change over time (15-20). This has led to mixed 287 
recommendations about what is the optimal MRI sequence to measure BMLs. As BMLs 288 
often appear larger on fluid-sensitive sequences compared to T1-weighted sequences (11, 19, 289 
20), authors often suggest measuring them using water-sensitive sequences (11, 34). Our 290 
study also found that BMLs appeared slightly larger on the T2-weighted sequences compared 291 
to the T1-weighted sequences. However, mixed findings from other studies (17, 18) has led 292 
to the hypothesis that a combination of both fluid-sensitive and GRE-type MRI sequences 293 
would result in superior accuracy in assesssing BMLs. One other study has assessed this in 294 
addition to ours; they observed no difference between a fluid sensitive sequence (IW-TSE) 295 
compared to a DESS sequence in detecting the overall prevalence or sensitivity to change 296 
over time (33). This led the authors to conclude that either sequence could be used for 297 
assessment of BML change in a clinical trial, which is consistent with our study findings.  298 
Studies which have used histology to characterise BMLs have offered great insight 299 
into the compositional charcteristics of BMLs. Zanetti et al were one of the first to examine 300 
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the histology of BMLs and found they consisted of oedema, fibrosis, trabecular bone 301 
changes, and necrosis (35). Combining different MRI sequences may offer new insights into 302 
the different cellular changes occurring in BMLs (36, 37). A study using a combination of 303 
fluid-sensitive and GRE-type MRI sequences showed significantly greater oedema, fibrosis 304 
and necrosis in BMLs present on both MRI sequences compared to BMLs present on only 305 
fluid-sensitive sequences (38). 306 
This study has several potential limitations. First, this study consisted of 394 307 
participants who had MRI scans at both time points, therefore excluding 705 from our larger 308 
cohort. However, the two groups were similar  in terms of age, sex, BMI, baseline cartilage 309 
defects and volume so our findings should be generalisable. Second, in our study, the initial 310 
response rate is lower than desirable (57%), but it is similar to other Australian cohort studies 311 
(39). The relationship between outcomes and exposures is not neccesarily biased due to a 312 
lower response rate (40). The study quality and validity should be judged with other criteria 313 
and not the response rate alone (41). Third, the BMLs assessed in this study were read by one 314 
reader who measured the BMLs on both sequences at the same time. Therefore the reader 315 
may have been more likely to pick up BMLs on each sequence because they were comparing 316 
the images from each sequence to each other. This may have led to an overestimate of BML 317 
presence on each sequence. However, this method does provide assurance because the reader 318 
was able to confidently document whether or not a BML was present on each sequence, 319 
meaning that BMLs were less likely to be missed by the reader. Forth, baseline WOMAC 320 
scales were categorised into tertiles as the data was not normally distributed and had a large 321 
amount of zero’s. While there is no consensus on the exact cut points to be used, we adopted 322 
cut-offs based on the expert consensus from an OA Expert Group from the GBD 2010 study.  323 
Conclusions 324 
BMLs were commonly seen on both T1-w GRE and T2-w FSE MRI sequences. They were 325 
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equivalently associated with clinical outcomes including symptoms, worsening of cartilage 326 
defects, cartilage volume loss, and TKR. Our study demonstrates that BMLs can be assessed 327 
on either MRI sequence alone with no clinical predictive advantage of either sequence.328 
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LIST OF ABBREVIATIONS 
2D, two-dimensions 
3D, three-dimensions 
AOANJRR, Australian Orthopaedic Association National Joint Replacement Registry  
BML(s), bone marrow lesions 
CI, confidence interval 
CV, coefficient of variation percentage 
GBD, Global Burden of Disease 
GRE, gradient recalled echo 
ICC, intra-class correlation coefficient 
IW-FS, intermediate weighted fat saturation  
MR, magnetic resonance 
MRI, magnetic resonance imaging  
OA, osteoarthritis 
PD-FS, proton density fat saturation 
RR, relative risk  
SPGR, spoiled gradient recalled acquisition in steady state 
STIR, short tau inversion recovery 
T1-w GRE, T1-weighted fat-suppressed 3D gradient-recalled acquisition MRI 
T2-w FSE, T2-weighted fat-suppressed 2D fast spin-echo MRI 
TASOAC, Tasmanian Older Adult Cohort 
TKR, total knee replacement 
WOMAC, Western Ontario and McMaster Universities OA Index 
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TABLES 
Table 1. Characteristics of participants split by the absence and presence of BMLs on any of 
the MRI sequences. 
 BMLs absent BMLs present p-value 
 n=163 n=231  
Age (year) 62.8 (7.2) 63.5 (7.3) 0.345 
Male sex (%) 46.6 50.6 0.433 
BMI (kg/m2) 27.4 (4.2) 27.8 (4.7) 0.297 
Radiographic OA (%) 54.4 59.6 0.312 
WOMAC scales    
    Pain (0-45) 0 (0, 3) 1 (0, 5) 0.547 
    Physical function (0-153) 0 (0, 9) 1 (0, 13) 0.223 
    Stiffness (0-18) 0 (0, 1) 0 0, 2) 0.670 
    Total WOMAC (0-216) 1 (0, 14) 3 (0, 20) 0.287 
Prevalent cartilage defects, 
baseline‡ (%) 30 61 <0.001 
Cartilage defect score increase 
(%) 55 73 <0.001 
Total cartilage volume, baseline 
(mm3) 17007 (4217) 16486 (3624) 0.219 
Absolute change in total 
cartilage volume (mm3) -774 (867) -926 (867) 0.145 
Incident TKR (%) 0 9.9 <0.001 
Values expressed in mean (standard deviation) or percentages. WOMAC scales are expressed as 
median (25th, 75th percentile). 
Bold font denotes significant p-value. 
n, number of people; BMI, body mass index; OA, osteoarthritis. ‡ Defined as grade 2 or higher.
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Table 2. Adjacent category logistic regression of baseline knee pain, physical function 
limitation, stiffness and total WOMAC on BMLs present on T2-w FSE, T1-w GRE, and both 
MRI sequences.  
Univariable 
 
Multivariable 1 
 
Multivariable 2  
OR (95% CI)  OR (95% CI)  OR (95% CI) 
Pain 
     
   T1 and T2 1.68 (1.13, 2.48) 
 
1.72 (1.15, 2.58) 
 
1.70 (1.13, 2.56) 
   T2-w FSE 1.65 (1.15, 2.37) 
 
1.69 (1.16, 2.45) 
 
1.66 (1.14, 2.43) 
   T1-w GRE 1.58 (1.11, 2.25) 
 
1.62 (1.13, 2.32) 
 
1.60 (1.11, 2.31)       
Physical function limitation 
    
   T1 and T2 1.57 (1.08, 2.27) 
 
1.54 (1.05, 2.27) 
 
1.57 (1.06, 2.32) 
   T2-w FSE 1.65 (1.15, 2.37) 
 
1.47 (1.04, 2.09) 
 
1.49 (1.05, 2.14) 
   T1-w GRE 1.53 (1.07, 2.18) 
 
1.50 (1.04, 2.16) 
 
1.52 (1.05, 2.21)       
Stiffness  
    
   T1 and T2 1.39 (0.99, 1.96) 
 
1.36 (0.96, 1.93) 
 
1.36 (0.95, 1.93) 
   T2-w FSE 1.38 (1.01, 1.90) 
 
1.36 (0.99, 1.89) 
 
1.34 (0.96, 1.87) 
   T1-w GRE 1.36 (0.99, 1.85) 
 
1.33 (0.97, 1.83) 
 
1.32 (0.96, 1.83)       
Total WOMAC score  
    
   T1 and T2 1.64 (1.12, 2.39) 
 
1.63 (1.10, 2.40) 
 
1.63 (1.10, 2.43) 
   T2-w FSE 1.57 (1.09, 2.24) 
 
1.56 (1.09, 2.24) 
 
1.56 (1.08, 2.25) 
   T1-w GRE 1.56 (1.11, 2.20) 
 
1.54 (1.08, 2.19) 
 
1.55 (1.08, 2.22) 
ORs represent the odds of moving to a higher category of pain, function, stiffness and total WOMAC 
for those with a BML on each sequence type compared to no BML on that sequence type.   
Multivariable 1 – adjusted for age, sex, BMI 
Multivariable 2 – further adjusted for presence of radiographic OA 
Bold denotes significant p-value 
OR, odds ratio; CI, confidence interval 
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Table 3. Linear regression estimates of change in knee pain, physical function limitation, 
stiffness and total WOMAC after 2.7 years on presence of BMLs on T2-w FSE, T1-w GRE, 
and both MRI sequences at baseline.  
Univariable 
β coefficient (95% 
CI) 
Multivariable 1 
β coefficient (95% CI) 
Multivariable 2 
β coefficient (95% CI) 
Change in pain  
  
   T1 and T2 1.14 (-0.16, 2.44) 1.10 (-0.19, 2.40) 1.34 (0.18, 2.50) 
   T2-w FSE 0.96 (-0.31, 2.23) 0.91 (-0.36, 2.17) 1.12 (0.06, 2.18) 
   T1-w GRE 1.12 (-0.15, 2.39) 1.07 (-0.18, 2.33) 1.37 (0.36, 2.39)     
Change in physical function limitation 
 
   T1 and T2 1.53 (-1.77, 4.82) 1.37 (-1.83, 4.57) 2.42 (-0.47, 5.32) 
   T2-w FSE 1.12 (-1.87, 4.11) 1.00 (-1.91, 3.92) 2.09 (-0.58, 4.75) 
   T1-w GRE 1.57 (-1.40, 4.55) 1.40 (-1.47, 4.26) 2.25 (-0.34, 4.84)     
Change in stiffness  
  
   T1 and T2 0.45 (-0.11, 1.02) 0.42 (-0.12, 0.97) 0.52 (0.05, 1.00) 
   T2-w FSE 0.36 (-0.16, 0.87) 0.37 (-0.11, 0.86) 0.45 (0.01, 0.89) 
   T1-w GRE 0.41 (-0.10, 0.91) 0.43 (-0.10, 0.97) 0.45 (0.03, 0.87)     
Change in total WOMAC  
 
   T1 and T2 3.07 (-1.70, 7.84) 2.82 (-1.82, 7.46) 4.13 (-0.13, 8.39) 
   T2-w FSE 2.30 (-2.02, 6.62) 2.11 (-2.12, 6.34) 3.51 (-0.41, 7.42) 
   T1-w GRE 3.19 (-1.53, 7.48) 2.90 (-1.71, 7.03) 3.93 (0.14, 7.72) 
β coefficient represent a 1 unit change of outcome score over 2.7 years for a BML present on 
each sequence type compared to no BML on that sequence type.   
Multivariable 1 – adjusted for age, sex, and BMI 
Multivariable 2 – further adjusted for presence of radiographic osteoarthritis and baseline 
WOMAC score  
Bold denotes a statistically significant result 
CI, confidence interval  
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Table 4. Log-binomial regression of worsening between site-specific cartilage defects over 
2.7 years  on site-specific presence of BMLs on T2-w FSE, T1-w GRE, and both MRI.  
Multivariable 
RR (95% CI) 
 
T1 and T2 T2-w FSE T1-w GRE 
    
Medial Tibial  1.66 (0.91, 3.00) 1.40 (0.78, 2.50) 1.59 (0.88, 2.88) 
Medial Femoral 2.51 (1.66, 3.79) 2.38 (1.58 , 3.59) 2.50 (1.65 , 3.78) 
Lateral Tibial 2.40 (1.52, 3.79) 2.49 (1.59, 3.89) 2.27 (1.44, 3.58) 
Lateral Femoral  4.63 (3.14, 6.84) 4.46 (3.02 , 6.6) 4.37 (2.96 , 6.46) 
Superior patellar 2.28 (1.52, 3.41) 2.13 (1.42, 3.21) 2.25 (1.53, 3.30) 
Inferior patellar  1.37 (0.82, 2.29) 1.46 (0.91, 2.34) 1.26 (0.79, 2.01) 
Medial Tibiofemoral 1.67 (1.26, 2.22) 1.51 (1.14, 2.00) 1.60 (1.21, 2.13) 
Lateral Tibiofemoral  1.79 (1.35, 2.39) 1.79 (1.35, 2.39) 1.73 (1.30, 2.31) 
Total Tibiofemoral  1.32 (1.08, 1.62) 1.26 (1.03, 1.54) 1.32 (1.08, 1.62) 
Total † 1.29 (1.08, 1.54) 1.25 (1.05, 1.48) 1.22 (1.04, 1.44) 
RR represents the risk of having a site-specific cartilage defect increase in those with a BML 
on each sequence type compared to no BML on that sequence type.  
Multivariable  – adjusted for age, sex, BMI, and baseline cartilage defects score 
†total of all site-specific cartilage defects 
Bold denotes a statistically significant result 
RR, relative risk; CI, confidence interval 
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Table 5. Mixed-effects model regression point estimates of mean change in site-specific 
cartilage volume loss over 2.7 years for site-specific BMLs present on T2-w FSE, T1-w 
GRE, and both T1 and T2, compared to the reference group with no BMLs. 
β coefficient represents 1mm3 change in cartilage volume over 2.7 years for a BML present 
on each sequence type compared to no BML on that sequence type.  
Multivariable 1 – adjusted for age, sex, and BMI 
† total of all site-specific cartilage volume loss 
Bold denotes a statistically significant result 
CI, confidence  
 
Multivariable  
β coefficient (95% CI)  
T1 & T2 T2-w FSE T1-w GRE 
    
Medial tibial  -28.35 (-134.43, 77.73) 11.44 (-87.32, 110.19) -38.55 (-142.61, 65.51) 
Medial femoral -95.90 (-192.67, 0.86) -106.21 (-197.34, -15.08) -89.58 (-186.69, 7.53) 
Lateral tibial -148.30 (-229.72, -66.89) -149.23 (-229.99, -68.47) -140.67 (-221.41, -59.92) 
Lateral femoral -23.91 (-96.98, 49.17) -30.54 (-102.07, 40.98) -19.97 (-91.86, 51.92) 
Superior patellar -174.77 (-314.79, -34.75) -169.69 (-306.42, -32.96) -144.39 (-278.99, -9.80) 
Inferior patellar -55.41 (-216.47, 105.65) -42.76 (-196.66, 111.14) -32.22 (-177.42, 112.98) 
Medial 
tibiofemoral -35.10 (-161.52, 91.31) -37.33 (-156.59, 81.93) -29.49 (-152.52, 93.54) 
Lateral 
tibiofemoral  -103.96 (-197.31, -10.60) -110.81 (-202.86, -18.77) -91.19 (-183.57, 1.20) 
Total tibiofemoral -78.40 (-227.35, 70.56) -106.93 (-251.49, 37.63) -26.99 (-169.58, 115.59) 
Total † -131.01 (-303.72, 41.69) -115.74 (-277.84, 46.37) -76.22 (-236.48, 84.05) 
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Figure 1. Flowchart of study participants  
Participants enrolled in TASOAC N=1100 
 
Attended baseline clinic N=1099 
 
Participants at first follow-up N=875 
 
 Did not continue N=224 
 
Untraceable n=4 
Refused to participate n=58 
Physically unable n=15 
Institutionalised n=2 
    
   
   
  
   
 
 
Participants with baseline and first follow-up T1 and T2-weighted MRI N=394 
 
No MRI scan performed  
   
 
Identified from electoral roll n=2530 
Eligible at baseline N=2135 
 
Ineligible N=395 
 
Unable to contact N=231 
 
Refused to participate N=804 
 
Participants with first follow-up MRIs N=405 
 
Untraceable MRI scans or only 
one MRI sequence available 
 
 
Did not attend clinic  N=1 
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Figure 2. Venn diagram of BML distribution. Yellow circle represents the BMLs on T2-w 
FSE, blue circle represents the BMLs on T1-w GRE, and the green overlapping area 
represents the BMLs present on both sequences. 
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Figure 3. BMLs are indicated by white arrows. 1a and 1b: BMLs present on T2-w FSE but 
not on T1-w GRE. 2a and 2B: BMLs present on T1-w GRE but not on T2-w FSE. 3a and 3b: 
BMLs present on both MRIs sequences.    
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Figure 4. Mean BML size (mm2) at each knee site on T2-w FSE and T1-w GRE.  
 
